Impact of Ultra-Rapid Insulin on Boost and Ease-Off in the Cambridge Hybrid Closed-Loop System for Individuals With Type 1 Diabetes
The use of Fiasp and Lyumjev during Boost or Ease-off resulted in comparable safety and efficacy to using insulin aspart and lispro.
Authors
- Roman Hovorka (ORCID: https://orcid.org/0000-0003-2901-461X)
- Lia Bally (ORCID: https://orcid.org/0000-0003-1993-7672)
- Malgorzata E. Wilinska (ORCID: https://orcid.org/0000-0002-1564-8083)
- Sara Hartnell (ORCID: https://orcid.org/0009-0002-8957-7924)
- Hood Thabit (ORCID: https://orcid.org/0000-0001-6076-6997)
- Julia Fuchs (ORCID: https://orcid.org/0000-0002-4497-0979)
- Charlotte K. Boughton (ORCID: https://orcid.org/0000-0003-3272-9544)
- Julia Katharina Mader (ORCID: https://orcid.org/0000-0001-7854-4233)
- Munachiso Nwokolo (ORCID: https://orcid.org/0000-0001-7200-6004)
- Mark L. Evans (ORCID: https://orcid.org/0000-0001-8122-8987)
- Rama Lakshman (ORCID: https://orcid.org/0000-0002-4341-1307)
- Lalantha Leelarathna (ORCID: https://orcid.org/0000-0001-9602-1962)
- Janet M. Allen
- Chloë Royston
Institutions
- Royal Free London NHS Foundation Trust (GB)
- Medical University of Graz (AT)
- University of Cambridge (GB)
- University Hospital of Bern (CH)
- Manchester Royal Infirmary (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Manchester University NHS Foundation Trust (GB)
- Wellcome/MRC Institute of Metabolic Science (GB)
- Imperial College London (GB)
Publication Details
- Journal
- Journal of Diabetes Science and Technology
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1177/19322968241289963
- Citations
- 2
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- Eli Lilly and Company
- Sanofi
- Insulet Corporation
- Dexcom
- Novo Nordisk
- Roche Diabetes Care
- Abbott Diabetes Care
- NIHR Cambridge Biomedical Research Centre